Last updated July 4, 2026
More: Clinical standards · Pharmacy partners · Is PepScribe legit?
No published trial has photographed a sermorelin before and after. The human evidence is narrower and mostly numerical: in the one published sermorelin treatment trial, 8 of 18 growth-hormone-deficient children met a response threshold within the first 6 months, and trials of other GHRH analogs measure body-composition change at 26 weeks. Lab markers move before anything visible does, and individual response varies widely.
Almost every image returned for this search is a self-posted pair of photographs with no control group, no blinding, and no published protocol behind it. That is not a reason to dismiss the people posting them. It is a reason to read them as what they are: one person’s report of a period in which several things changed at once.
The rest of this page uses the alternative available: what human studies of sermorelin and related growth hormone-releasing hormone (GHRH) analogs measured, in whom, and over what window. That is a narrower answer than a transformation gallery, and it is one you can check.
Sermorelin is a 29-amino-acid analog of human GHRH, described in a 1999 review in BioDrugs as the shortest synthetic peptide with the full biological activity of GHRH. The same review reports that intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary, and that the intravenous 1 microgram/kg response is rapid enough to be used as a diagnostic test for growth hormone deficiency.
The mechanism sits one step upstream of growth hormone itself, which is the source of most of the variation in results. The peptide sends a signal. What arrives downstream depends on how a particular pituitary answers it.
The table below separates two things that consumer timelines usually merge: what has been measured in a controlled study, and what people report. Both are listed, and each row says which it is.
| Window | What is measured or reported | Evidence behind it |
|---|---|---|
| Days 1 to 14 | Injection-site redness or itching; changes in dreams and sleep depth | Patient report, no controlled data at this window |
| Weeks 2 to 6 | First follow-up IGF-1 draw in typical clinical practice | Clinical practice; the GH response to sermorelin is documented as rapid (1999 review) |
| Weeks 6 to 12 | Subjective energy, sleep and recovery reports cluster here online | Unblinded self-report, no control group |
| Week 12 | Usual first formal reassessment: repeat labs, waist, weight, symptoms | Clinical practice, not a trial endpoint |
| Week 26 (6 months) | The window at which GHRH-analog trials in adults measured visceral fat change | Randomised placebo-controlled human trials of tesamorelin, 410 participants |
| 6 to 18 months | In the sermorelin trial, the height-velocity gain seen early was maintained | Human trial, 18 children, 1987 |
Order matters more than speed here. Anything visible in a photograph sits at the slow end of the chain, several steps after the part of the response that can be measured in a tube of blood.
The clearest published treatment result for the sermorelin sequence is a 1987 Lancet trial in growth-hormone-deficient children. It is old, small, and in a population that has little in common with an adult reading a peptide forum. It is also the trial with an actual before and after in it, so it is worth stating precisely.
Sermorelin belongs to a family, and the adult human data sits mostly with its relatives. Tesamorelin, a different GHRH analog approved by the US FDA in November 2010 for the reduction of excess abdominal fat in people with HIV-associated lipodystrophy, carries the largest controlled dataset in the family. Different molecule, different population, so read across it with care rather than treating it as sermorelin evidence.
| Compound and study | Who was studied | Endpoint and window |
|---|---|---|
| Sermorelin, Lancet 1987 | 18 GH-deficient prepubertal children | Height velocity over 6 to 18 months |
| CJC-1295, JCEM 2006 | Healthy adults aged 21 to 61 | GH and IGF-1 secretion across two randomised trials of 28 and 49 days |
| Tesamorelin, AIDS 2011 | 410 people with HIV and abdominal adiposity | Inflammatory markers against visceral fat change, 2 mg daily for 26 weeks |
| Tesamorelin, JAMA 2014 | 50 people with HIV and abdominal fat accumulation | Visceral fat and liver fat, randomised and placebo-controlled |
| Tesamorelin, AIDS 2017 | 806 people across two phase III trials | Response set in advance by FDA as at least 8% visceral fat reduction |
| GHRH agonist MR-409, PNAS 2021 | 16 pigs with induced kidney disease (animal model) | Cardiac and renal structure after 4 to 6 weeks of daily dosing |
A 2026 review in the American Journal of Sports Medicine notes how quickly injectable peptides have been marketed to patients, and argues that clinicians need to know the evidence behind them. Marketing moves faster than trials, and photo galleries are the fastest-moving part of it.
Clinicians running a growth hormone axis therapy watch numbers rather than appearance, because the numbers move earlier and cannot be posed. IGF-1 is the central one: it is the downstream marker the peptide is meant to raise, and it shows whether the pituitary answered at all.
A rising IGF-1 confirms the signal landed. It does not by itself prove a benefit you can feel, which is why symptoms and body measurements are tracked next to it rather than replaced by it.
Trials of this drug class answer this question by defining a responder in advance, which is the most useful habit consumer content borrows least. Across two phase III tesamorelin trials in 806 participants, the threshold set by FDA in advance was at least an 8% reduction in visceral fat, and the published analysis reports that the majority of treated patients met it. The corollary is stated in the same sentence: some did not.
In the 1987 sermorelin trial the pattern is the same shape. 12 of 18 children improved on the measure, and 8 met the pre-set threshold. A group average would have hidden both facts.
Those five are clinical considerations rather than trial-validated predictors of response. No study in this source set ranked them.
No trial of sermorelin in this source set measured weight loss. The fat data in this drug class comes from tesamorelin, where the measured endpoint was visceral adipose tissue rather than scale weight, in people with HIV-associated abdominal fat accumulation. A 2014 JAMA trial in 50 participants looked at visceral and liver fat; a 2017 analysis of 806 participants linked visceral fat reduction to changes in liver enzymes.
Sleep is the most reported effect online and the least measured in the literature. No sermorelin study in this source set used sleep quality as an endpoint, so the weeks-two-to-six sleep reports stand as patient experience, not trial data. A 2020 review in Translational Andrology and Urology describes growth hormone secretagogues as a potential novel adjunctive therapy for some of the symptoms of hypogonadism, including body composition, which is a statement about promise rather than about established use.
The nearest measured cognitive endpoint in the class is a 6-month phase 2 open-label trial comparing tesamorelin with standard of care for neurocognitive impairment in people with HIV and abdominal obesity, which is a different question in a different population.
The items below are what patients and clinicians describe in practice. No controlled sermorelin safety trial in adults appears in this source set, so treat them as reported experience rather than trial-quantified rates.
Compounded medications are prepared for an individual patient under a prescription and are not FDA-approved drug products. Compounded sermorelin is not an FDA-approved drug, and no page, photo or forum thread changes that. The published sermorelin literature sits in the diagnosis and treatment of growth hormone deficiency, principally in children.
What is verifiable is where a dose comes from. Every dose PepScribe dispenses is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain. That is the part of a before and after photo you can never check on a stranger.
The practical difference between a plan and a protocol copied from a thread is that a plan has a baseline, a review date and a person accountable for both. A licensed clinician decides whether any therapy is appropriate, and a prescription is never automatic.
It depends entirely on which endpoint you are tracking. Blood markers are the earliest thing that can be measured, which is why a follow-up IGF-1 draw is usually scheduled within the first six weeks. Body-composition endpoints in growth hormone-releasing hormone analog trials were measured at 26 weeks, and the one published sermorelin treatment trial used a 6-month window. Individual response varies, and some people in these trials did not meet the response threshold at all.
No. There is no published trial of sermorelin in healthy adults that reports a typical result, so nothing can honestly be called typical. Trials of related growth hormone-releasing hormone analogs define responders explicitly rather than describing an average patient: in two phase III tesamorelin trials the threshold set in advance was at least an 8% reduction in visceral fat, and the analysis reports responders and non-responders separately.
No. Sermorelin is a 29-amino-acid analog of growth hormone-releasing hormone that signals the anterior pituitary to release its own growth hormone, according to a 1999 review of its clinical use. Recombinant human growth hormone is the hormone itself, given directly. Because sermorelin acts one step upstream, any response depends on how well a given pituitary answers the signal.
Ask what else changed during the same period, whether training, diet, testosterone therapy or a GLP-1 medication were running alongside; ask what the baseline and follow-up lab values were; ask over how many weeks the two photos were taken; and ask how many patients on the same protocol did not post a photo. A result with no denominator behind it is a selection effect rather than evidence.
CJC-1295: Research, Mechanism & Legal Status | RedditWhat the research says about CJC-1295, the long-acting GHRH analog, DAC vs. non-DAC variants, the Teichman 2006 trial, ipamorelin pairings, side effects, and FDA transitional regulatory status.
Does Sermorelin Work? What the Evidence Actually Shows | RedditDoes sermorelin work? A clinician-grounded look at the clinical evidence, how sermorelin stimulates growth hormone, who is a candidate, and what realistic outcomes look like under physician supervision.How to Get Sermorelin Online: The Legitimate Path | RedditHow to get sermorelin online legally in 2026: the telehealth prescription path step by step, what a licensed clinician evaluates, how 503A pharmacy dispensing works, and the red flags that separate real prescription sermorelin from research-grade vials.
Ipamorelin: Research, Mechanism & Legal Status | RedditWhat the research says about Ipamorelin, a selective ghrelin-receptor agonist and growth-hormone-releasing peptide. Mechanism, Novo Nordisk discovery, comparative GHRP selectivity, and current US regulatory posture.The expectation the poster started with was immediate: inject, then fall into deep sleep that night, and what he found once he began reading were accounts describing no sleep effect at all. A realistic before and after runs on a longer clock, with sleep quality, recovery and body composition judged over weeks to months of consistent nightly dosing, and the honest range of outcomes includes no perceptible change.
Posted on Reddit
A licensed clinician reviews your health history and decides whether sermorelin is appropriate for you. Compounded in the USA by licensed 503A pharmacies.